May 12, 2020
Neurocrine uses option to licence rights to Idorsia’s inhibitor for treatment of rare children epilepsy
Neurocrine Biosciences has exercised its option to license the global rights to Idorsia’s ACT-709478, as it plans to initiate a Phase 2 study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.